Medical News / Broadcasting from ESC 2023: Mavacamten Use Can Reduce Need for Septal Reduction Therapy in oHCM

Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the need for septal reduction therapy (SRT) among patients with obstructive hypertrophic cardiomyopathy (HCM). Results of the study, which were presented at the European Society of Cardiology (ESC) Congress 2023, indicate the rate of SRT or SRT eligibility in the placebo-crossover group was more than twice that of the mavacamten only arm, with use of mavacamten also associated with improvements in resting and Valsalva left ventricular outflow tract (LVOT) gradients. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful ... read more
At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its ... read more
For frail elderly patients with atrial fibrillation, switching from a vitamin K antagonist (VKA) treatment to ... read more
For endocrinologists and the diabetes care team, GLP-1 receptor agonists have been a familiar face for ... read more